APA (7th ed.) Citation

Junying Wang, Jeffery White, Kenneth J. Sansone, Lynda Spelman, Rodney Sinclair, Xin Yang, . . . Zheng Wei. (2023). Rademikibart (CBP‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis. Wiley.

Chicago Style (17th ed.) Citation

Junying Wang, Jeffery White, Kenneth J. Sansone, Lynda Spelman, Rodney Sinclair, Xin Yang, Wubin Pan, and Zheng Wei. Rademikibart (CBP‐201), a Next‐generation Monoclonal Antibody Targeting Human IL‐4Rα: Two Phase I Randomized Trials, in Healthy Individuals and Patients with Atopic Dermatitis. Wiley, 2023.

MLA (9th ed.) Citation

Junying Wang, et al. Rademikibart (CBP‐201), a Next‐generation Monoclonal Antibody Targeting Human IL‐4Rα: Two Phase I Randomized Trials, in Healthy Individuals and Patients with Atopic Dermatitis. Wiley, 2023.